There are two points there, Mr. Chair.
I can't speak to need in the U.S. for AstraZeneca. The fact is that the vaccine is not yet approved for use in the U.S. by their regulatory authority, and yet there's manufacturing taking place there. Working with AstraZeneca and the U.S. government, we were able to effectively get an exchange of doses to bring forward 1.5 million doses because Canada has a contract with AstraZeneca. We would then pony up for the U.S. at a later date, when appropriate, but it was more just getting an advance on the doses owed to Canada under the contract by using the U.S. government as a go-between.